Trial reportScientific reports2022
Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Nationwide attribute-based cross-classification reveals distinct risk patterns of major complications in ADPKD.Clinical and experimental nephrology · 2026Article
- Attribute-based cross-classification reveals sex- and age-specific prognostic impact of anemia in ADPKD.Clinical and experimental nephrology · 2026Article
- Uric acid, vitamin D, and left ventricular hypertrophy: Unveiling cardiovascular risks - a retrospective cross-sectional study.Medicine · 2026Article
- Timing of urate-lowering therapy and risk of kidney failure and mortality in CKD: an application of the parametric G-formula.Clinical kidney journal · 2026Article
- Association of anemia with long-term renal prognosis in autosomal dominant polycystic kidney disease using time-series analysis.Scientific reports · 2026Article
- Increased serum uric acid-to-urinary urate excretion ratio with the kidney function decline in male CKD patients without diabetes: a retrospective cohort study.BMC nephrology · 2025Article
- Multiscale Imaging of Human Adipose Tissue: A Neglected Partner in Proteinuria Linked to Obesity.Biomedicines · 2025Review
- Hyperuricemia and progression of IgA nephropathy: time to consider early uric acid lowering therapy?Annals of medicine and surgery (2012) · 2025Article
- Hyperuricemia in Chronic Kidney Disease: Emerging Pathophysiology and a Novel Therapeutic Strategy.International journal of molecular sciences · 2025Review
- Attribute based cross classification analyses from the BRIGHTEN study reveal that therapeutic responsiveness to erythropoiesis stimulating agents predicts cardiorenal prognosis in renal anemia.Scientific reports · 2025Article
- Predictive Modeling of Heterogeneous Treatment Effects in RCTs: A Scoping Review.JAMA network open · 2025Article
- Potential clinical impact of predictive modeling of heterogeneous treatment effects: scoping review of the impact of the PATH Statement.medRxiv : the preprint server for health sciences · 2025Article
- Hyperuricemia-induced complications: dysfunctional macrophages serve as a potential bridge.Frontiers in immunology · 2025Review
- Association between serum uric acid and kidney disease with pediatric focus.Childhood kidney diseases · 2024Review
- Hyperuricemia and its related diseases: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024Review
- J-shaped Association between Serum Uric Acid Levels and the Prevalence of a Reduced Kidney Function: A Cross-sectional Study Using Japanese Health Examination Data.Internal medicine (Tokyo, Japan) · 2024Article
- Factors associated with early-onset intracranial aneurysms in patients with autosomal dominant polycystic kidney disease.Journal of nephrology · 2024Article
- Efficacy of dotinurad in patients with severe renal dysfunction.Clinical and experimental nephrology · 2024Article
- Gasdermin D promotes hyperuricemia-induced renal tubular injury through RIG-I/caspase-1 pathway.iScience · 2023Article
- Prevalence and clinical association of hyperechoic crystal deposits on ultrasonography in patients with chronic kidney disease: a cross-sectional study from a single center.Journal of nephrology · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 20 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attribute-based medicine is essential for patient-centered medicine. To date, the groups of patients with chronic kidney disease (CKD) requiring urate-lowering therapy are clinically unknown. Herein, we evaluated the efficacy of febuxostat using a cross-classification, attribute-based research approach. We performed post hoc analysis of multicenter, randomized, double-blind, placebo-controlled trial data for 395 patients with stage 3 CKD and asymptomatic hyperuricemia. Participants were divided into febuxostat or placebo groups and subcohorts stratified and cross-classified by proteinuria and serum creatinine concentrations. In patients stratified based on proteinuria, the mean eGFR slopes were significantly higher in the febuxostat group than in the placebo group (P = 0.007) in the subcohort without proteinuria. The interaction between febuxostat treatment and presence of proteinuria in terms of eGFR slope was significant (P for interaction = 0.019). When cross-classified by the presence of proteinuria and serum creatinine level, the mean eGFR slopes significantly differed between the febuxostat and placebo groups (P = 0.040) in cross-classified subcohorts without proteinuria and with serum creatinine level ≥ median, but not in the cross-classified subcohorts with proteinuria and serum creatinine level < median. Febuxostat mitigated the decline in kidney function among stage 3 CKD patients with asymptomatic hyperuricemia without proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.